{
  "event_id": "b70edeee9006",
  "ticker": "YMAB",
  "company_name": "Y-mAbs Therapeutics",
  "drug_name": "DANYELZA",
  "result": "approved",
  "pdufa_date": "2024-03-20",
  "approval_type": {
    "status": "found",
    "value": "bla",
    "source": "websearch:Phase 2 (accelerated approval)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.708616",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Relapsed/refractory high-risk neuroblastoma",
    "source": "websearch:Phase 2 (accelerated approval)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.708617",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "naxitamab",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.198928",
    "error": null
  },
  "mechanism_of_action": {
    "status": "found",
    "value": "GD2 inhibitor",
    "source": "legacy_migration",
    "confidence": 0.75,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": "2026-01-10T12:42:32.828950",
    "error": null,
    "note": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:43:48.137725",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:Phase 2 (accelerated approval)",
    "confidence": 0.85,
    "evidence": [
      "Phase 2 (accelerated approval)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.708601",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:Phase 2 (accelerated approval)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.708610",
    "error": null
  },
  "effect_size": {
    "status": "found",
    "value": "ORR 45% in r/r neuroblastoma",
    "source": "websearch:Phase 2 (accelerated approval)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.708612",
    "error": null
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "p_value_numeric": null,
  "nct_ids": [
    "NCT03363373"
  ],
  "phase3_study_names": [
    "A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow"
  ],
  "prior_crl_reason": null,
  "enrollment": {
    "count": 122,
    "type": "ESTIMATED",
    "nct_id": "NCT03363373",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:31:55.985393"
  },
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": true
  },
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "date": null,
    "outcome": null,
    "vote_for": null,
    "vote_against": null
  },
  "is_single_arm": {
    "value": true,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=SINGLE_GROUP",
      "allocation=NA"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-10T13:15:56.751189",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "global",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['SPAIN', 'DENMARK', 'HONG KONG', 'UNITED STATES', 'FRANCE']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-10T13:15:56.751219",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "is_biosimilar": {
    "value": false,
    "status": "found",
    "source": "mab_without_biosimilar_suffix",
    "confidence": 0.8,
    "tier": 3,
    "evidence": [
      "monoclonal antibody without -xxxx suffix: naxitamab"
    ],
    "searched_sources": [
      "known_db",
      "patterns",
      "suffix_pattern",
      "approval_type"
    ],
    "last_searched": "2026-01-10T23:29:31.534917",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "is_first_in_class": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "crl_reason_type": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "warning_letter_date": {
    "value": null,
    "status": "confirmed_none",
    "source": "websearch_fda",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [
      "No FDA warning letter found in search"
    ],
    "searched_sources": [
      "websearch_fda"
    ],
    "last_searched": "2026-01-11T04:23:56.095641",
    "error": null
  },
  "fda_483_date": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "fda_483_observations": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "cdmo_name": {
    "status": "not_searched",
    "value": null,
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "note": null
  },
  "pai_date": {
    "value": null,
    "status": "not_found",
    "source": "",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T13:55:08.036877",
    "error": null,
    "note": null,
    "has_value": false,
    "needs_retry": true,
    "is_complete": false
  },
  "clinical_hold_history": {
    "value": null,
    "status": "confirmed_none",
    "source": "websearch_clinical_hold",
    "confidence": 0.0,
    "tier": null,
    "evidence": [],
    "searched_sources": [
      "websearch_clinical_hold"
    ],
    "last_searched": "2026-01-10T13:55:09.045847",
    "error": null,
    "note": null,
    "has_value": false,
    "needs_retry": false,
    "is_complete": true
  },
  "days_to_pdufa": -661,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.919947",
  "original_case_id": "175521092901",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:36:57.299341",
  "enriched_at": "2026-01-11T20:44:37.364354",
  "needs_manual_review": false,
  "review_reasons": [],
  "migrated_at": "2026-01-10T12:42:32.828975",
  "schema_version": "3.0",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T06:38:03.717721"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T06:38:03.717729"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Grants Accelerated Approval to Naxitamab-gqgk Combo for ... FDA Approves New IV Tx for Neuroblas"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:44:22.796866",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:44:29.985880",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:44:36.168563",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:44:26.320992",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "FDA grants accelerated approval to naxitamab for high-risk ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:44:37.364342",
    "search_status": "FOUND"
  }
}